The majority of studies assumed that elevated serum CRP levels in patients with malignancy constituted a bodily response, secondary to tumor necrosis, local tissue damage and inflammation caused by cytokines released from leukocytes infiltrating the tumor microenvironment, in particular IL-6 [23, 24]. This evidence concerns the gene IL6 and neoplasm.